Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Incyte (INCY) PT Lowered to $76 at RBC Capital
May 2, 2018 8:30 AM EDTRBC Capital lowered its price target on Incyte (NASDAQ: INCY) to $76.00 (from $77.00) while maintaining a Outperform rating.
Analyst Brian Abrahams commented, "Jakafi continues to perform solidly and we believe provides a strong valuation foundation; while we acknowledge visibility on life cycle plans, later-stage pipeline... More
Incyte (INCY) Misses Q1 EPS by 2c
May 1, 2018 7:08 AM EDTIncyte (NASDAQ: INCY) reported Q1 EPS of ($0.01), $0.02 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $382 million versus the consensus estimate of $390.05 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
... More